Syros Pharmaceuticals SYRS Stock
Syros Pharmaceuticals Price Chart
Syros Pharmaceuticals SYRS Financial and Trading Overview
| Syros Pharmaceuticals stock price | 5 USD |
| Previous Close | 3.34 USD |
| Open | 3.34 USD |
| Bid | 0 USD x 3000 |
| Ask | 0 USD x 1000 |
| Day's Range | 3.21 - 3.35 USD |
| 52 Week Range | 2.42 - 11 USD |
| Volume | 52.03K USD |
| Avg. Volume | 85.01K USD |
| Market Cap | 66.73M USD |
| Beta (5Y Monthly) | 1.659154 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.81 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.8 USD |
SYRS Valuation Measures
| Enterprise Value | -35899572 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.72321427 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 5.3957644 |
| Price/Book (mrq) | 0.61938447 |
| Enterprise Value/Revenue | -2.903 |
| Enterprise Value/EBITDA | 0.257 |
Trading Information
Syros Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 1.659154 |
| 52-Week Change | -68.23% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 11 USD |
| 52 Week Low | 2.42 USD |
| 50-Day Moving Average | 3.28 USD |
| 200-Day Moving Average | 4.19 USD |
SYRS Share Statistics
| Avg. Volume (3 month) | 85.01K USD |
| Avg. Daily Volume (10-Days) | 49.26K USD |
| Shares Outstanding | 20.6M |
| Float | 16.73M |
| Short Ratio | 7.09 |
| % Held by Insiders | 1.02% |
| % Held by Institutions | 54.53% |
| Shares Short | 625.84K |
| Short % of Float | 3.20% |
| Short % of Shares Outstanding | 3.04% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -1151.70% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -49.81% |
| Return on Equity (ttm) | -110.088% |
Income Statement
| Revenue (ttm) | 12.37M USD |
| Revenue Per Share (ttm) | 0.69 USD |
| Quarterly Revenue Growth (yoy) | -46.00000000000000000000000000000000% |
| Gross Profit (ttm) | 14.88M USD |
| EBITDA | -139508000 USD |
| Net Income Avi to Common (ttm) | -93297000 USD |
| Diluted EPS (ttm) | -3.99 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 165.8M USD |
| Total Cash Per Share (mrq) | 8.05 USD |
| Total Debt (mrq) | 63.17M USD |
| Total Debt/Equity (mrq) | 59.18 USD |
| Current Ratio (mrq) | 7.373 |
| Book Value Per Share (mrq) | 5.231 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -129949000 USD |
| Levered Free Cash Flow (ttm) | -84043376 USD |
Profile of Syros Pharmaceuticals
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 35 CambridgePark Drive |
| ZIP | 02140 |
| Phone | 617 744 1340 |
| Website | https://www.syros.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 117 |
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Q&A For Syros Pharmaceuticals Stock
What is a current SYRS stock price?
Syros Pharmaceuticals SYRS stock price today per share is 5 USD.
How to purchase Syros Pharmaceuticals stock?
You can buy SYRS shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Syros Pharmaceuticals?
The stock symbol or ticker of Syros Pharmaceuticals is SYRS.
Which industry does the Syros Pharmaceuticals company belong to?
The Syros Pharmaceuticals industry is Biotechnology.
How many shares does Syros Pharmaceuticals have in circulation?
The max supply of Syros Pharmaceuticals shares is 28.52M.
What is Syros Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Syros Pharmaceuticals PE Ratio is now.
What was Syros Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Syros Pharmaceuticals EPS is -5.81 USD over the trailing 12 months.
Which sector does the Syros Pharmaceuticals company belong to?
The Syros Pharmaceuticals sector is Healthcare.
Syros Pharmaceuticals SYRS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}